

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

UEHARA ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/006865

FILED: 24 JUNE 2004

U.S. APPLICATION NO: 10/560,940

35 USC §371 DATE: 15 DECEMBER 2005

FOR: TABLET COMPRISING FLUVASTATIN AND CARMELLOSE
CALCIUM

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed February 16, 2007. Since it is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the reference cited on the attached form(s) PTO-1449.

A Copy of this reference and the English Equivalent are enclosed herewith.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PC/4-33240A
APPLICATION NO.
10/560,940
APPLICANT
UEHARA ET AL.
FILING DATE
DECEMBER 15, 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM						<input type="checkbox"/>	<input checked="" type="checkbox"/>
AN						<input type="checkbox"/>	<input checked="" type="checkbox"/>
AO						<input type="checkbox"/>	<input checked="" type="checkbox"/>
AP						<input type="checkbox"/>	<input checked="" type="checkbox"/>
AQ						<input type="checkbox"/>	<input checked="" type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Shokuhin Tenkabusu Handbook, Maruzen KK, p. 71-76, (1989), JP-A-10-226644 and English Equivalents thereof.
AS	
AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7877


John W. Kung
Attorney for Applicants
Reg. No. 44,199

Date: 3/5/87